Compare CIVB & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | CIVB | ANL |
|---|---|---|
| Founded | 1884 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 571.6M | 611.1M |
| IPO Year | 2012 | 2022 |
| Metric | CIVB | ANL |
|---|---|---|
| Price | $27.40 | $13.86 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 1 |
| Target Price | ★ $26.60 | $20.00 |
| AVG Volume (30 Days) | ★ 143.7K | 139.0K |
| Earning Date | 04-22-2026 | 04-10-2026 |
| Dividend Yield | ★ 2.90% | N/A |
| EPS Growth | ★ 31.34 | N/A |
| EPS | ★ 1.41 | N/A |
| Revenue | ★ $19,023,000.00 | N/A |
| Revenue This Year | $14.88 | $36.02 |
| Revenue Next Year | $5.99 | N/A |
| P/E Ratio | $19.44 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $19.84 | $0.88 |
| 52 Week High | $29.97 | $17.25 |
| Indicator | CIVB | ANL |
|---|---|---|
| Relative Strength Index (RSI) | 45.65 | 54.40 |
| Support Level | $27.00 | $12.45 |
| Resistance Level | $29.31 | $15.29 |
| Average True Range (ATR) | 0.53 | 0.96 |
| MACD | -0.05 | -0.09 |
| Stochastic Oscillator | 50.00 | 45.32 |
Civista Bancshares Inc is a financial holding company. Operating through its subsidiary, it engages in the business of community banking. Its business activity involves collecting customer deposits, making loans, purchasing securities, and offering trust services to its clients. The company's loan portfolio includes commercial and agricultural, commercial real estate-owner occupied, commercial real estate non-owner occupied, residential real estate, real estate construction, and consumer loans. The majority of its revenues are derived from the interest and fees gained on loans.
Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.